On April 6, 2021 Sapience Therapeutics, Inc., a clinical stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, reported multiple poster presentations, including a late-breaker, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, which is being held in a virtual format (Press release, Sapience Therapeutics, APR 6, 2021, View Source [SID1234577642]). The posters will be available on April 10, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentations are as follows:
Title: Tumor uptake and predictable PK of ST101 – a peptide antagonist of C/EBPβ – in patients with advanced unresectable and metastatic solid tumors
Abstract Control Number: 5106
Presentation Time: The e-poster will be available on the AACR (Free AACR Whitepaper) website on Saturday, April 10, 2021
Session Type: E-Poster Session (late-breaker)
Session Category: Experimental and Molecular Therapeutics
Session Title: New Targets
Permanent Abstract Number: LB114
Title: C/EBPβ antagonist peptide, ST101, as a therapeutic approach in breast cancer
Abstract Control Number: 3578
Presentation Time: The e-poster will be available on the AACR (Free AACR Whitepaper) website on Saturday, April 10, 2021
Session Type: E-Poster Session
Session Category: Experimental and Molecular Therapeutics
Session Title: Biological Therapeutic Agents
Permanent Abstract Number: 959
Title: β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activity
Abstract Control Number: 3677
Presentation Time: The e-poster will be available on the AACR (Free AACR Whitepaper) website on Saturday, April 10, 2021
Session Type: E-Poster Session
Session Category: Experimental and Molecular Therapeutics
Session Title: Biological Therapeutic Agents
Permanent Abstract Number: 964
More details can be found at View Source
About ST101
ST101 is a peptide inhibitor of C/EBPβ, which is a transcription factor overexpressed in many cancers that regulate cellular differentiation and promote tumor survival and proliferation. ST101 significantly decreases the expression of C/EBPβ target genes/proteins involved in cell survival, proliferation and differentiation including BCL-2, MCL-1, BIRC5/survivin, cyclins and ID family of proteins. ST101 has been demonstrated to induce selective cancer cell cytotoxicity across a variety of tumor types, including but not limited to breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML. C/EBPβ is expressed and active in cancer cells but not active in normal cells (post-differentiation), providing a therapeutic opportunity.